SecBot SecBot
SECBOTREPLAY Home › Report › PHVS

PHVS · Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs…

Pharvaris N.V. · PRESS-RELEASE filed May 12, 2026 at 16:05 ET

At the news

NEUTRALIMPACT 5/10

PRESS-RELEASE filed May 12, 2026 at 16:05 ET

Pharvaris reported Q1 2026 EPS of €-0.59 (IFRS), a narrower loss vs €-0.85 a year ago, with cash of €247M extended by a $132M offering into 2028. The key catalysts are the CHAPTER-3 Phase 3 HAE prophylaxis data due in 3Q2026 and the NDA submission for deucrictibant IR in 1H2026.

  • Q1 2026 loss per share €-0.59 vs €-0.85 YoY (IFRS basis)
  • Cash and equivalents €247M as of March 31, 2026, down from €292M at Dec 31, 2025
  • Closed $132.3M underwritten offering post-quarter, extending cash runway into 2028
  • CHAPTER-3 Phase 3 topline data for deucrictibant XR expected in 3Q2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access